Abstract
The open prospective combined cytogenetic and clinical study investigated the impact of biological therapy Rituximab on number and structure of chromosomes in Rheumatoid arthritis patients. The purpose of this study was to investigate safety of Rituximab on chromosomes as well as cytotoxic therapy Methotrexate. A total of 8 seropositive Rheumatoid arthritis patients were analyzed for primary end point of eventual cytotoxic effect of Rituximab. Assessment was done before and 1 month later, actually 2 weeks after the administration of full course of Rituximab in infusion. Patients suffering from active Rheumatoid arthritis were randomly assigned according to established protocol to receive infusion of Rituximab in a full dose of 2.0 grams divided in a two doses of 1.0 gram on days 1 and 15. The lymphocytes from peripheral blood were cultured according to Moorhead method. The results obtained from this investigation showed that normal male and female karyogram was found after the full therapy of Rituximab. The results from this study, that was done on a rather small number of subjects, indicate that Rituximab does not express either clastogenic or aneugenic effects. But, co-finding of this study was that Methotrexate had a side effect on chromosomal aberration in one female RA patient, and after discontinuation of this treatment the normal karyogram was observed.
Highlights
Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease that affect approximately, of the adult population and leads to irreversible joint destruction and permanent disability
B lymphocytes play central role in the pathogenesis of Rheumatoid arthritis and in secretion of auto antibodies. e final impact of such depletion is the significant decrease of rheumatoid factor and other disease activity parameters in a patient serum
E purpose of this study and primary goal was to investigate the impact of Rituximab on the number and structure of chromosomes in rheumatoid arthritis patients ( )
Summary
Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory disease that affect approximately , of the adult population and leads to irreversible joint destruction and permanent disability. The evaluative disease activity requires intensive treatment with disease-modifying anti rheumatic drugs (DMARDs) including biological therapy for rheumatoid arthritis. Rituximab is a genetically engineered human/mouse chimerical novel anti-CD monoclonal antibody that selectively binds to C + pre-B and mature B lymphocytes ( ) causing the profound and prolonged depletion of peripheral-blood B cell subpopulation ( , ). E final impact of such depletion is the significant decrease of rheumatoid factor and other disease activity parameters in a patient serum. E purpose of this study and primary goal was to investigate the impact of Rituximab on the number and structure of chromosomes in rheumatoid arthritis patients ( ). The secondary aim was to observe the effect of cytotoxic therapy Methotrexate on the same chromosomes
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
